Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (symbol: VXRT) is a clinical-stage biotechnology company dedicated to transforming vaccine delivery through its innovative oral recombinant vaccine platform. Founded in 2004, Vaxart's primary focus is the development of vaccines in tablet form, offering a needle-free alternative that is easy to administer and store. This proprietary technology aims to revolutionize the global vaccine market, addressing common diseases such as Coronavirus, Norovirus, Seasonal Influenza, Respiratory Syncytial Virus (RSV), and Human Papillomavirus (HPV).
Headquartered in the United States, Vaxart operates in a single segment focused exclusively on the discovery and development of these groundbreaking oral recombinant protein vaccines. The company has made significant strides in the clinical development of its diverse pipeline, with several candidates currently undergoing trials. Vaxart’s oral vaccines are designed to simplify distribution and administration, potentially increasing vaccination rates and improving global health outcomes.
Recent achievements for Vaxart include the ongoing development and testing of its oral COVID-19 vaccine candidate, which has shown promise in preclinical studies and early-phase clinical trials. This innovation could play a crucial role in global vaccination efforts, especially in regions where cold-chain requirements pose logistical challenges. Other notable projects include the development of oral vaccines for Norovirus and Influenza, which are also advancing through various stages of clinical testing.
Financially, Vaxart remains focused on strategic partnerships and funding opportunities to support its research and development initiatives. The company's recent financial results for the full year ended December 31, 2023, and the first quarter ended March 31, 2024, reflect its ongoing commitment to advancing its oral vaccine candidates through clinical trials and towards regulatory approval.
For more information and the latest updates, contact Vaxart Media Relations: Mark Herr (mherr@vaxart.com, 203-517-8957) or Investor Relations: Andrew Blazier (IR@vaxart.com, 646-871-8486).
Vaxart (NASDAQ: VXRT) has announced a strategic shift prioritizing its bivalent norovirus vaccine candidate following encouraging clinical trial results. The company has completed six trials demonstrating robust immunogenicity and safety in young adults and the elderly. Vaxart plans to report topline data from ongoing Phase 2 studies in mid-2023 and Q3 2023, respectively. The company ended 2022 with $95.7 million in cash but reported a net loss of $107.8 million, up from $70.5 million in 2021. Vaxart's research and development expenses surged to $81.1 million due to increased headcount and clinical trial costs, while revenue fell to $0.1 million from $0.9 million in 2021.
Vaxart, Inc. (NASDAQ: VXRT) will provide a business update and financial results for the year ending December 31, 2022, on March 15, 2023, after market close. A conference call with senior management is scheduled for the same day at 4:30 p.m. ET. Vaxart focuses on developing oral recombinant vaccines through a unique delivery system aimed at eliminating needle-stick injuries. Their product pipeline includes vaccines for coronavirus, norovirus, seasonal influenza, RSV, and HPV, along with existing intellectual property protections.
Vaxart, Inc. (NASDAQ: VXRT) announced the dosing of the first subject in its Phase 2 clinical trial for an oral bivalent norovirus vaccine on February 14, 2023. This trial aims to establish optimal vaccine dosing ahead of a possible Phase 3 trial. The vaccine demonstrated robust immunogenicity in Phase 1b, with IgA responses of 78% and 93% for GI.1 and GII.4 strains, respectively. Approximately 135 healthy adults will participate, analyzing safety and immunogenicity. The global norovirus market is estimated at over $10 billion, with significant annual health impacts in the U.S. Vaxart expects to report topline data in mid-2023.
Vaxart, Inc. (NASDAQ: VXRT) has appointed Phillip Lee as its new Chief Financial Officer, effective immediately. Lee brings nearly 15 years of experience in corporate finance, M&A, and advisory roles, having facilitated over $20 billion in transactions and raised over $1 billion in capital. CEO Andrei Floroiu expressed excitement about Lee's contribution to Vaxart's mission of combating infectious diseases through its oral vaccine platform. Vaxart focuses on developing innovative oral vaccines for various diseases, including COVID-19 and HPV, leveraging its proprietary delivery technology.
Vaxart, Inc. (Nasdaq: VXRT) announced a new study funded by the Bill & Melinda Gates Foundation to assess an oral norovirus vaccine aimed at protecting breastfeeding mothers and their infants. The study will investigate whether the vaccine induces antibodies in breast milk and transfers them to infants. Norovirus sickens approximately 21 million people in the U.S. annually, posing significant health risks, especially to children under five. The research aligns with Vaxart’s commitment to global access for low- and middle-income countries if the vaccine is effective.
Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on November 29, 2022. The presentation will focus on Vaxart’s Phase II trial results for its oral pill COVID-19 vaccine candidate, which recently showed positive top-line results. Vaxart specializes in developing oral recombinant vaccines and aims to create vaccines for various diseases, including COVID-19 and HPV.
Vaxart reported positive developments in its oral vaccine platform during the third quarter of 2022, including encouraging Phase II results for its COVID-19 candidate, demonstrating both serum and mucosal immunity.
The company ended the quarter with $114.8 million in cash but posted a net loss of $29.3 million, up from $17.6 million year-over-year, primarily due to increased R&D costs. With promising data in norovirus trials and key milestones expected in 2023, Vaxart aims to address significant market opportunities.
Vaxart, Inc. (NASDAQ: VXRT) will report its third-quarter financial results on November 8, 2022, after market close. A conference call will follow at 4:30 p.m. ET, where senior management will discuss the company's updates. Vaxart is focused on developing oral recombinant vaccines that can be delivered via tablets, aiming to provide alternatives for various viral infections, including COVID-19, norovirus, seasonal influenza, and RSV. Their innovative delivery platform reduces risks associated with traditional vaccinations, and the company has pending patent applications for its technology.
Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker and Dr. James Cummings will present at the World Vaccine Congress Europe 2022 in Barcelona on October 13. Dr. Tucker will discuss nasal mucosal responses to a SARS-CoV-2 oral tablet vaccine at 11:30 a.m. CET, while Dr. Cummings will present findings on immune responses to norovirus G1.1 in elderly subjects at 12:00 p.m. CET. Vaxart develops oral recombinant vaccines aimed at various viruses, emphasizing delivery without refrigeration and eliminating needle-stick risks.
Vaxart, Inc. (Nasdaq: VXRT) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will feature key executives including CEO Andrei Floroiu, CSO Dr. Sean Tucker, and CMO Dr. James Cummings, and will be available for viewing on the Company’s Events page starting September 12 at 7:00 a.m. ET. Vaxart specializes in developing oral recombinant vaccines, aiming to create accessible, needle-free vaccination options for various diseases.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
What is Vaxart, Inc. known for?
When was Vaxart, Inc. founded?
What is Vaxart's proprietary technology?
Where is Vaxart, Inc. headquartered?
What are some diseases Vaxart's vaccines target?
How is Vaxart's oral vaccine beneficial?
What recent achievements has Vaxart made?
What is Vaxart's financial condition?
How can I contact Vaxart for more information?
What segment does Vaxart operate in?
